Form 8-K · Current Report · Filed 2025-10-23
West Pharmaceutical Services Reports Q3 2025 Earnings Beat and Raises Guidance
West Pharmaceutical Services, Inc. announced its third-quarter 2025 financial results on October 23, 2025, reporting net sales of $804.6 million, up 7.7% year-over-year, and adjusted-diluted EPS of $1.96, surpassing the previous guidance. The company achieved organic growth of 5.0% and raised its full-year 2025 revenue guidance to a range of $3.060 billion to $3.070 billion and adjusted-diluted EPS guidance to a range of $7.06 to $7.11. The strong performance was driven by double-digit growth in the HVP Components segment and a solid contribution from the Contract Manufacturing segment. The company also repurchased 552,593 shares for $134.0 million under its share repurchase program during the first nine months of 2025.
- Filer
- West Pharmaceutical Services Inc. WST · NYSE
- Filed
- Accession
- 0000105770-25-000090
- CIK
- 0000105770
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$277.00
Next session
+7.4%
Since filing
+23.1%
Latest close
$340.96
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from WST reporting the same item, with the next session's move:
About West Pharmaceutical Services Inc.
West Pharmaceutical Services Inc. is a leading global provider of innovative solutions for injectable drug administration. The company specializes in designing and manufacturing packaging and delivery systems specifically for pharmaceuticals, biologics, and vaccines. West Pharmaceutical Services plays a crucial role in ensuring the safety and efficiency of drug delivery through its products, which include stoppers, seals, containers, and pre-fillable syringe systems. Catering to a diverse range of healthcare and pharmaceutical clients, the company's offerings are integral in the development and distribution of injectable therapies across various therapeutic categories, including oncology, diabetes, and infectious diseases. As a partner to some of the world's leading pharmaceutical companies, West Pharmaceutical Services contributes significantly to advancements in medical treatments and healthcare technologies globally. Its commitment to quality and innovation underscores its importance in the pharmaceutical supply chain and enhances drug efficacy, ultimately impacting patient care and treatment outcomes.
Never miss another WST filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.